Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?

Affiliations

¹ Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Diseases, University of Pisa, 56124 Pisa, Italy. Electronic address: stefano.delprato@med.unipi.it.

Comment

Stefano Del Prato. Lancet Diabetes Endocrinol. 2014 Nov.

. 2014 Nov;2(11):856-8.

doi: 10.1016/S2213-8587(14)70185-8. Epub 2014 Sep 1.

¹ Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Diseases, University of Pisa, 56124 Pisa, Italy. Electronic address: stefano.delprato@med.unipi.it.

No abstract available

Comment on

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. Gough SC, et al. Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1. Lancet Diabetes Endocrinol. 2014. PMID: 25190523 Clinical Trial.